Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles

Creative Commons License

Alp E., Cirak T., DEMİRBİLEK M., TÜRK M., GÜVEN E.

TURKISH JOURNAL OF BIOLOGY, vol.41, no.5, pp.719-733, 2017 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 5
  • Publication Date: 2017
  • Doi Number: 10.3906/biy-1612-17
  • Journal Name: TURKISH JOURNAL OF BIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.719-733
  • Keywords: PHBV nanoparticle, folate targeting, etoposide, targeted drug delivery, osteosarcoma, CANCER-THERAPY, PROTEIN ADSORPTION, DRUG-RELEASE, MICROPARTICLES, APOPTOSIS, ASSAY
  • Hacettepe University Affiliated: Yes

Abstract

Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200-250 nm and zeta potential range of -21 and -27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposide-loaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.